243 A.3d 241
Pa. Super. Ct.2020Background
- Reglan (Wyeth) and its generic metoclopramide (Teva/PLIVA) were FDA-approved with longstanding label warnings about risk of tardive dyskinesia; Wyeth updated Reglan in July 2004 to advise against use longer than 12 weeks.
- Mrs. Zitney used metoclopramide intermittently (2004–2009) for migraine-associated nausea; she later developed movement disorders that her expert attributed to metoclopramide exposure.
- Appellants filed a multi-count products-liability action; by 2019 only Teva and PLIVA remained. Appellants conceded the label content was adequate but argued defendants failed to notify Mrs. Zitney’s prescribing physician (Dr. Tobin) via a Dear Health Care Provider (DHCP) letter.
- The trial court held Pennsylvania law requires drug warnings be conveyed via the product’s package insert and does not impose a duty to send DHCP letters; because Teva and PLIVA used adequate labels, no breach occurred and summary judgment was entered for defendants.
- The Superior Court affirmed, reasoning the learned intermediary doctrine is satisfied by adequate physician-directed package labeling and that Pennsylvania law does not impose the additional duty to send DHCP letters; Appellants’ contention that breach was a jury question was waived below.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether a drug manufacturer must notify prescribing physicians by DHCP letter (beyond including warnings in the package insert) | Zitney: manufacturers must directly inform physicians who foreseeably rely on manufacturer communications; DHCP letter was required here | Teva/PLIVA: duty is met by including FDA‑approved warnings in the product label/insert; no duty to send DHCP letters | Court: No duty to send DHCP letters; package insert warnings suffice under Pennsylvania law |
| Whether breach of the duty to warn (in manner of communication) is a jury question | Zitney: manner of notification (no DHCP) raises factual dispute for jury | Defendants: no legal duty beyond label; therefore no triable issue | Court: Issue of existence of duty is a question of law (decided for defendants); plaintiffs waived jury‑question argument below |
Key Cases Cited
- Summers v. Certainteed Corp., 997 A.2d 1152 (Pa. 2010) (standard of appellate review for summary judgment)
- Hahn v. Richter, 673 A.2d 888 (Pa. 1996) (negligence is the recognized basis for inadequate‑warning claims against drug manufacturers)
- Demmler v. SmithKline Beecham Corp., 671 A.2d 1151 (Pa. Super. 1996) (a product is defective if it lacks adequate warnings; proper directions can negate defect)
- Simon v. Wyeth Pharmaceuticals, Inc., 989 A.2d 356 (Pa. Super. 2009) (Pennsylvania applies the learned intermediary doctrine to prescription drugs)
- Dion v. Graduate Hosp. of Univ. of Penna., 520 A.2d 876 (Pa. Super. 1987) (warning duty for prescription drugs is directed to the prescribing physician)
- Daniel v. Wyeth Pharmaceuticals, Inc., 15 A.3d 909 (Pa. Super. 2011) (adequacy of warnings given to prescribing physicians is the focus in failure‑to‑warn claims)
- Truax v. Roulhac, 126 A.3d 991 (Pa. Super. 2015) (existence of a legal duty is a question of law)